CycloSPORINE Injectable Product

Phase 1

CycloSPORINE Injectable Product is one of 34 therapeutic programs targeting Alopecia Areata. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Alopecia AreataActive, not recruiting

Alopecia AreataPhase 1

Active, not recruiting

Competition

Competitive Landscape

35 competitors in Alopecia Areata

#DrugCompanyPhaseTrials

Trexall

Jazz Pharmaceuticals

Approved

3 2

Otezla

Amgen

Approved

2 3

Kenalog

BBausch Health Americas, Inc.

Approved

11 4

Zolymbus

AbbVie

Approved

1 5

Daliresp

AstraZeneca

Approved

1 6

Xeljanz

PPrism Pharmaceuticals

Approved

8 7

Anzupgo

Zocor

1 9

Xalatan

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

1 10

Aspercreme Warming

AAveritas Pharma, Inc.

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Active, not recruiting

Alopecia Areata

NCT07029204

Clinical

Trials by Indication[1]

Alopecia Areata1 trial

Pilot Study on Intralesional Cyclosporine for Alopecia Areata

Active, not recruiting·UUniversity of California, Davis·Phase 1·NCT07029204·2 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for CycloSPORINE Injectable Product. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for CycloSPORINE Injectable Product. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — University of California, Davis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 1[1]
Company: UUniversity of California, Davis

CycloSPORINE Injectable Product

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Alopecia Areata1 trial

References

Drug Info

Quick Facts

Related News